Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


27.02.2017

3 AJR Am J Roentgenol
1 Am J Clin Pathol
2 Ann Thorac Surg
2 Arch Pathol Lab Med
1 BMC Cancer
1 BMJ
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Chest
1 Clin Lung Cancer
1 Clin Nucl Med
2 J Cancer Res Clin Oncol
2 J Clin Oncol
2 J Surg Oncol
6 J Thorac Oncol
15 Lung Cancer
15 Lung Cancer (Auckl)
1 Mol Carcinog
4 N Engl J Med
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. KLEEDEHN M, Kim DH, Lee FT, Lubner MG, et al
    Preoperative Pulmonary Nodule Localization: A Comparison of Methylene Blue and Hookwire Techniques.
    AJR Am J Roentgenol. 2016;207:1334-1339.
    PubMed     Text format     Abstract available

  2. VOGL TJ, Eckert R, Naguib NN, Beeres M, et al
    Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation.
    AJR Am J Roentgenol. 2016;207:1340-1349.
    PubMed     Text format     Abstract available

  3. FUJISAKI A, Aoki T, Kasai T, Kinoshita S, et al
    Pleomorphic Carcinoma of the Lung: Relationship Between CT Findings and Prognosis.
    AJR Am J Roentgenol. 2016.
    PubMed     Text format     Abstract available


    Am J Clin Pathol

  4. MATHIESON W, Marcon N, Antunes L, Ashford DA, et al
    A Critical Evaluation of the PAXgene Tissue Fixation System: Morphology, Immunohistochemistry, Molecular Biology, and Proteomics.
    Am J Clin Pathol. 2016;146:25-40.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  5. GOROSPE L, Munoz-Molina GM, Carvajal-Serrano P, Garcia-Latorre R, et al
    Intrathoracic Desmoid Tumor Arising at Thoracotomy Site Mimicking Lung Cancer Pleural Recurrence.
    Ann Thorac Surg. 2017;103:e291.
    PubMed     Text format    

  6. BAISI A, Raveglia F, De Simone M, Cioffi U, et al
    Do Tumor Size and Carcinoembryonic Antigen Level Affect Surgical Management of Partially Solid Early-Stage Lung Cancer?
    Ann Thorac Surg. 2017;103:1036.
    PubMed     Text format    


    Arch Pathol Lab Med

  7. BAHAMON BN, Gao F, Danaee H
    Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
    Arch Pathol Lab Med. 2016;140:1397-1403.
    PubMed     Text format     Abstract available

  8. DOLLED-FILHART M, Locke D, Murphy T, Lynch F, et al
    Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
    Arch Pathol Lab Med. 2016;140:1259-1266.
    PubMed     Text format     Abstract available


    BMC Cancer

  9. DERMAN BA, Macklis JN, Azeem MS, Sayidine S, et al
    Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
    BMC Cancer. 2017;17:141.
    PubMed     Text format     Abstract available


    BMJ

  10. DYER O
    Drug companies settle claim of misleading doctors on cancer survival data.
    BMJ. 2016;353:i3361.
    PubMed     Text format    


    Cancer Epidemiol Biomarkers Prev

  11. SHEN X, Wang L, Zhu L
    Spatial analysis of regional factors and lung cancer mortality in China, 1973-2013.
    Cancer Epidemiol Biomarkers Prev. 2017 Feb 21. pii: cebp.0922.2016.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. LI Y, Sun N, Lu Z, Sun S, et al
    Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Cancer Lett. 2017 Feb 18. pii: S0304-3835(17)30125.
    PubMed     Text format     Abstract available


    Chest

  13. GESTHALTER YB, Koppelman E, Bolton R, Slatore CG, et al
    Evaluations of Implementation at Early-adopting Lung Cancer Screening Programs: Lessons Learned.
    Chest. 2017 Feb 18. pii: S0012-3692(17)30222-2. doi: 10.1016/j.chest.2017.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  14. NGUYEN NA, Isfahanian N, Pond G, Hanna W, et al
    A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).
    Clin Lung Cancer. 2017 Jan 31. pii: S1525-7304(17)30036.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  15. JANSSEN I, Wolf KI, Chui CH, Millo CM, et al
    Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key?
    Clin Nucl Med. 2017;42:211-213.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  16. UDAGAWA H, Niho S, Kirita K, Umemura S, et al
    Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
    J Cancer Res Clin Oncol. 2017 Feb 20. doi: 10.1007/s00432-017-2350.
    PubMed     Text format     Abstract available

  17. MIGLIORINO MR, Santo A, Romano G, Cortinovis D, et al
    Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
    J Cancer Res Clin Oncol. 2017 Feb 18. doi: 10.1007/s00432-016-2326.
    PubMed     Text format     Abstract available


    J Clin Oncol

  18. RUSTHOVEN CG, Palma DA, Senan S, Kavanagh BD, et al
    The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2017 Feb 21:JCO2016720003. doi: 10.1200/JCO.2016.72.0003.
    PubMed     Text format    

  19. YANG JC, Ahn MJ, Kim DW, Ramalingam SS, et al
    Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
    J Clin Oncol. 2017 Feb 21:JCO2016703223. doi: 10.1200/JCO.2016.70.3223.
    PubMed     Text format     Abstract available


    J Surg Oncol

  20. MASAI K, Sakurai H, Suzuki S, Asakura K, et al
    Clinicopathological features of colloid adenocarcinoma of the lung: A report of six cases.
    J Surg Oncol. 2016;114:211-5.
    PubMed     Text format     Abstract available

  21. SPARBER-SAUER M, Seitz G, Kirsch S, Vokuhl C, et al
    The impact of local control in the treatment of type II/III pleuropulmonary blastoma. Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS).
    J Surg Oncol. 2017;115:164-172.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  22. HUANG YJ, Huang TW, Lin FH, Chung CH, et al
    Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-based Cohort Analysis.
    J Thorac Oncol. 2017 Jan 31. pii: S1556-0864(17)30045.
    PubMed     Text format     Abstract available

  23. HENDRIKS LE, Hochstenbag M, Dingemans AM
    Screening for Brain Metastases in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e21.
    PubMed     Text format    

  24. VERNON J, Hanna WC
    Response to Screening for Brain Metastases in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e22.
    PubMed     Text format    

  25. DICKHOFF C, Senan S, Dahele M
    Radical-Intent Treatment of Lung Cancer after Prior Thoracic Radiotherapy.
    J Thorac Oncol. 2017;12:e26-e27.
    PubMed     Text format    

  26. PIOTROWSKA Z, Sequist LV
    Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.
    J Thorac Oncol. 2017;12:419-421.
    PubMed     Text format    

  27. NOTSUDA H, Bradbury PA, Tsao MS
    HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy.
    J Thorac Oncol. 2017;12:422-424.
    PubMed     Text format    


    Lung Cancer

  28. LAM VK, Bentzen SM, Mohindra P, Nichols EM, et al
    Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;104:52-57.
    PubMed     Text format     Abstract available

  29. KAWAGUCHI K, Yokoi K, Niwa H, Ohde Y, et al
    A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801).
    Lung Cancer. 2017;104:79-84.
    PubMed     Text format     Abstract available

  30. LILLIE SE, Fu SS, Fabbrini AE, Rice KL, et al
    What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration.
    Lung Cancer. 2017;104:38-44.
    PubMed     Text format     Abstract available

  31. PAZ-ARES LG, Zimmermann A, Ciuleanu T, Bunn PA, et al
    Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;104:45-51.
    PubMed     Text format     Abstract available

  32. AWAN S, Crosby V, Potter V, Hennig I, et al
    Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.
    Lung Cancer. 2017;104:75-78.
    PubMed     Text format     Abstract available

  33. CHANG GC, Tseng CH, Hsu KH, Yu CJ, et al
    Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Lung Cancer. 2017;104:58-64.
    PubMed     Text format     Abstract available

  34. SESUMI Y, Suda K, Mizuuchi H, Kobayashi Y, et al
    Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Lung Cancer. 2017;104:85-90.
    PubMed     Text format     Abstract available

  35. SU XD, Xie HJ, Liu QW, Mo YX, et al
    The prognostic impact of tumor volume on stage I non-small cell lung cancer.
    Lung Cancer. 2017;104:91-97.
    PubMed     Text format     Abstract available

  36. MESSARITAKIS I, Politaki E, Plataki M, Karavassilis V, et al
    Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Lung Cancer. 2017;104:16-23.
    PubMed     Text format     Abstract available

  37. KATO T, Masuda N, Nakanishi Y, Takahashi M, et al
    Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Lung Cancer. 2017;104:111-118.
    PubMed     Text format     Abstract available

  38. AWAD MM, Chu QS, Gandhi L, Stephenson JJ, et al
    An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
    Lung Cancer. 2017;104:126-130.
    PubMed     Text format     Abstract available

  39. TAYLOR KL, Hagerman CJ, Luta G, Bellini PG, et al
    Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial.
    Lung Cancer. 2017 Feb 14. pii: S0169-5002(17)30029.
    PubMed     Text format     Abstract available

  40. OKUMA Y, Hosomi Y, Nakahara Y, Watanabe K, et al
    High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Lung Cancer. 2017;104:1-6.
    PubMed     Text format     Abstract available

  41. SHIN B, Shin S, Chung MJ, Lee H, et al
    Different histological subtypes of peripheral lung cancer based on emphysema distribution in patients with both airflow limitation and CT-determined emphysema.
    Lung Cancer. 2017;104:106-110.
    PubMed     Text format     Abstract available

  42. KOH YW, Lee SJ, Park SY
    Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Lung Cancer. 2017;104:31-37.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  43. TIAN H, Li X, Jiang W, Lv C, et al
    High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
    Lung Cancer (Auckl). 2016;7:53-61.
    PubMed     Text format     Abstract available

  44. SAWADA S, Suehisa H, Ueno T, Sugimoto R, et al
    Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography.
    Lung Cancer (Auckl). 2016;7:45-51.
    PubMed     Text format     Abstract available

  45. CARNIO S, Di Stefano RF, Novello S
    Fatigue in lung cancer patients: symptom burden and management of challenges.
    Lung Cancer (Auckl). 2016;7:73-82.
    PubMed     Text format     Abstract available

  46. LEPRIEUR EG, Fallet V, Cadranel J, Wislez M, et al
    Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.
    Lung Cancer (Auckl). 2016;7:83-90.
    PubMed     Text format     Abstract available

  47. TRAN PN, Klempner SJ
    Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.
    Lung Cancer (Auckl). 2016;7:91-97.
    PubMed     Text format     Abstract available

  48. SEIJO LM
    Electromagnetic navigation bronchoscopy: clinical utility in the diagnosis of lung cancer.
    Lung Cancer (Auckl). 2016;7:111-118.
    PubMed     Text format     Abstract available

  49. BAKER S, Fairchild A
    Radiation-induced esophagitis in lung cancer.
    Lung Cancer (Auckl). 2016;7:119-127.
    PubMed     Text format     Abstract available

  50. RICHARD PJ, Rengan R
    Oligometastatic non-small-cell lung cancer: current treatment strategies.
    Lung Cancer (Auckl). 2016;7:129-140.
    PubMed     Text format     Abstract available

  51. DE SA VK, Coelho JC, Capelozzi VL, de Azevedo SJ, et al
    Lung cancer in Brazil: epidemiology and treatment challenges.
    Lung Cancer (Auckl). 2016;7:141-148.
    PubMed     Text format     Abstract available

  52. MINAMI S, Ogata Y, Ihara S, Yamamoto S, et al
    Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer.
    Lung Cancer (Auckl). 2016;7:35-44.
    PubMed     Text format     Abstract available

  53. MARKOU A, Zavridou M, Lianidou ES
    miRNA-21 as a novel therapeutic target in lung cancer.
    Lung Cancer (Auckl). 2016;7:19-27.
    PubMed     Text format     Abstract available

  54. LEGIUS B, Van Den Broecke S, Muylle I, Ninane V, et al
    Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer.
    Lung Cancer (Auckl). 2016;7:149-152.
    PubMed     Text format     Abstract available

  55. KISS N
    Nutrition support and dietary interventions for patients with lung cancer: current insights.
    Lung Cancer (Auckl). 2016;7:1-9.
    PubMed     Text format     Abstract available

  56. CHEN YY, Huang TW, Chang H, Lee SC, et al
    Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer.
    Lung Cancer (Auckl). 2016;7:29-34.
    PubMed     Text format     Abstract available

  57. ESFAHANI K, Cohen V
    HSP90 as a novel molecular target in non-small-cell lung cancer.
    Lung Cancer (Auckl). 2016;7:11-17.
    PubMed     Text format     Abstract available


    Mol Carcinog

  58. FENG C, Xia Y, Zou P, Shen M, et al
    Curcumin analogue L48H37 induces apoptosis through ROS-mediated endoplasmic reticulum stress and STAT3 pathways in human lung cancer cells.
    Mol Carcinog. 2017 Feb 20. doi: 10.1002/mc.22633.
    PubMed     Text format     Abstract available


    N Engl J Med

  59. MOK TS, Wu YL, Ahn MJ, Garassino MC, et al
    Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:629-640.
    PubMed     Text format     Abstract available

  60. MAOZ A, Rennert G, Gruber SB
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    

  61. RECH AJ, Vonderheide RH
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    

  62. ROSENBERG SA, Tran E, Robbins PF
    T-Cell Transfer Therapy Targeting Mutant KRAS.
    N Engl J Med. 2017;376:e11.
    PubMed     Text format    


    PLoS One

  63. JIAO DM, Yan L, Wang LS, Hu HZ, et al
    Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA- transcription factor-target gene network.
    PLoS One. 2017;12:e0172470.
    PubMed     Text format     Abstract available

  64. NARITA M, Shimura E, Nagasawa A, Aiuchi T, et al
    Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
    PLoS One. 2017;12:e0172115.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  65. TANG Y, Wang Z, Li Z, Kim J, et al
    High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.
    Proc Natl Acad Sci U S A. 2017 Feb 21. pii: 201612229.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: